Coronary Artery Disease

FDA panel again rejects wider use of J&J's Xarelto

A panel of Food and Drug Administration experts again opposed expanding use of Johnson & Johnson's blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

Jan 16, 2014
popularity not rated yet | comments 0

Latest Spotlight News

Infant cooing, babbling linked to hearing ability

Infants' vocalizations throughout the first year follow a set of predictable steps from crying and cooing to forming syllables and first words. However, previous research had not addressed how the amount ...